{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:35:07Z","timestamp":1790411707166,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170266"],"award-info":[{"award-number":["81170266"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302503"],"award-info":[{"award-number":["81302503"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","award":["QML20150601"],"award-info":[{"award-number":["QML20150601"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ijcard.2016.04.103","type":"journal-article","created":{"date-parts":[[2016,4,17]],"date-time":"2016-04-17T22:47:11Z","timestamp":1460933231000},"page":"293-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study"],"prefix":"10.1016","volume":"215","author":[{"given":"Wuxiang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.04.103_bb0005","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0010","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0015","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0020","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0025","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0030","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.atherosclerosis.2010.09.027","article-title":"Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population","volume":"213","author":"Cui","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0035","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.atherosclerosis.2010.04.015","article-title":"Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients","volume":"211","author":"Cariou","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0040","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.atherosclerosis.2014.04.001","article-title":"Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease","volume":"234","author":"Li","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0055","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease","volume":"64","author":"Rosenson","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0060","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","article-title":"Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment","volume":"62","author":"Werner","year":"2014","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0070","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0075","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0080","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1161\/01.CIR.103.3.462","article-title":"Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring","volume":"103","author":"Wu","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0085","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1001\/jama.291.21.2591","article-title":"Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study","volume":"291","author":"Liu","year":"2004","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0090","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jacc.2014.11.019","article-title":"Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study","volume":"65","author":"Qi","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0095","first-page":"532","article-title":"Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis","volume":"21","author":"Liu","year":"2014","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0100","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1161\/STROKEAHA.107.502807","article-title":"Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing project","volume":"39","author":"Zhao","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.echo.2007.11.011","volume":"21","author":"Stein","year":"2008","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0120","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2011.12.043","article-title":"Plasma PCSK9 levels and clinical outcomes in the TNT (treating to new targets) trial: a nested case\u2013control study","volume":"59","author":"Huijgen","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0125","first-page":"370","article-title":"Circulating PCSK9 predicts future risk of cardiovascular events independently of established risk factors","volume":"35","author":"Leander","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0130","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/eurheartj\/ehu095","article-title":"The Sirt1 activator SRT3025 provides atheroprotection in Apoe\u2212\/\u2212 mice by reducing hepatic PCSK9 secretion and enhancing LDLR expression","volume":"36","author":"Miranda","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0140","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1194\/jlr.M051326","article-title":"Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin","volume":"55","author":"Kuhnast","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0145","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0150","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2014.02.538","article-title":"Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects","volume":"63","author":"Lambert","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0155","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1194\/jlr.P023994","article-title":"Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia","volume":"53","author":"Huijgen","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ijcard.2016.04.103_bb0160","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/STROKEAHA.111.646596","article-title":"Risk factors for progression of carotid intima-media thickness and total plaque area: a 13-year follow-up study: the Tromso study","volume":"43","author":"Herder","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0165","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.atherosclerosis.2011.07.006","volume":"220","author":"Spence","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0170","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1161\/01.STR.0000042207.16156.B9","article-title":"Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy","volume":"33","author":"Spence","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0175","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/CIRCULATIONAHA.104.522706","article-title":"Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromso study","volume":"112","author":"Johnsen","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0180","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.metabol.2013.01.005","article-title":"Association of serum proprotein convertase subtilisin\/kexin type 9 with carotid intima media thickness in hypertensive subjects","volume":"62","author":"Lee","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.ijcard.2016.04.103_bb0185","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2012.10.065","article-title":"Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials","volume":"226","author":"D'Ascenzo","year":"2013","journal-title":"Atherosclerosis"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316307641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316307641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T08:48:19Z","timestamp":1716022099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316307641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":37,"alternative-id":["S0167527316307641"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.04.103","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.04.103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}